- ANI Pharmaceuticals (NASDAQ:ANIP -9.4%) Q1 results: Revenues: $18.8M (+72.5%); COGS: $2.8M (+7.7%); R&D Expense: $0.4M (+5.3%); SG&A: $4.8M (+29.7%); Operating Income: $9.6M (+174.3%); Net Income: $4.4M (+29.4%); EPS: $0.38 (+15.2%); Quick Assets: $165.6M (-2.0%).
- 2015 Guidance: Net revenues: $80M - 88M (unch); Cost of sales: 15 - 17.5 (unch)%; Opearting expenses: $16.2M - 16.5M (unch); R&D: ~3M (unch); non-GAAP EPS: $2.44 - 2.67; non-GAAP EBITDA: $48.8M - 53.1M (unch); effective tax rate: 36.8%.
ANI Pharma revenues up 73% in Q1, provides 2015 guidance
Recommended For You
More Trending News
About ANIP Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ANIP | - | - |
ANI Pharmaceuticals, Inc. |